Feasibility and toxicity of combination chemotherapy with ifosfamide, vinorelbine, cisplatin versus ifosfamide, vinorelbine in patients with advanced non small cell lung cancer

Anticancer Research

Volumn 17, Issue 4 A, 1997, Pages 2795-2798

  Mencoboni, Manlio ^a   Lerza, Roberto ^a   Castello, Giorgio ^a   Arboscello, Eleonora ^a   Barsotti, Bianca Paola ^a   Cerruti, Alessandro ^a   Ballarino, Paola ^a   Botta, Marco ^a   Bogliolo, Giuseppe ^a   Pannacciulli, Ivo ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b DIMI   (Italy)

Author keywords

Cisplatin; Ifosfamide; Non small cell lung cancer; Vinorelbine

Indexed keywords

CISPLATIN; IFOSFAMIDE; NAVELBINE; ONDANSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOXICITY; FEASIBILITY STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; SYMPTOM; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; VINBLASTINE;

EID: 0030755796     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Vokes E, Huffman, P, Masters G, Golomb H, Drinkard L, Krauss S: Ifosfamide based chemotherapy for non small cell lung cancer: phase I/II at the University of Chicago. Semin Oncol 23, suppl. 7: 15-18, 1996.
2. Yokes E: Integration of vinorelbine into chemotherapy strategies for non small cell lung cancer. Oncology 9: 565-577, 1995.
3. Lilenbaum RC, Green MR: Novel chemotherapeutic agents in the treatment of non small cell lung cancer. J Clin Oncol 11: 1391-1402, 1993.
4. Feigal EG, Christian M, Cheson B: New chemoiherapeutic agents in non small cell lung cancer. Semin Oncol 20: 185-201, 1993.
5. Le Chevalier T, Brisgand D, Douillard JY et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non small cell lung cancer: Result of an European multicenter trial including 612 patients. J Clin Oncol 12: 360-367, 1994.
6. Hoffman P, Masters G, Drinkard L, Kraus S, Samuels B, Golomb H, Vokes E: Ifosfamide based combination chemotherapy in advanced non small cell lung cancer two phase I studies. Semin oncol 23, suppl. 6: 11-15, 1996.
7. Marantz A, Lewi D, Litovska S: Phase II study of vinorelbine and ifosfamide for non-small cell lung cancer. Proc Am Soc Clin Oncol 13: 325, 1995 (abs).
8. Morere JF, Brunet A, Druan A et al: Ifosfamide and vinorelbine in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 13: 344, 1994 (abs).
9. Vallejo C, Romero A, Ferez J et al: Ifosfamide and vinorelbine as first-line chemotherapy for advanced non small cell lung carcinoma. Proc Am Soc Clin Oncol 14: 375, 1995 (abs).
10. Hoffman PC, Drinkard LC, Masters GA et al: Ifosfamide plus navelbine: A phase I study in advanced non small cell lung cancer. Proc Am Soc Clin Oncol 14; 358, 1995 (abs).
11. McVie JG: Non-small cell lung cancer: metanalysis of efficacy of chemotherapy. Semin Oncol 23, suppl. 7: 12-14, 1996.
12. Johnson DH: Ifosfamide in non-small cell lung cancer. Semin Oncol 23 suppl 6: 7-10, 1996.
13. Mountain CF: A new international staging system for lung cancer. Chest 89: 225-233,1986.
14. Baldini E, Tibaldi C, Ardizzoni A, Chella A, Angeletti CA, Silvano G, Conte PF: Phase II study of cisplatin (CDDP), ifosfamide (IPX) and vinorelbine (VNR) in stage IIIB-IV NSCLC. Lung Cancer 11, suppl. 1: 430, 1994.
15. WHO hand book for reporting results of cancer treatment. WHO Offset Publication, Geneva, n. 48, 1980.
16. Gottfried M, Yelin A, Shapira Y, Burillon JP, Levanon A: Navelbine (N) ifosfamide (I) cisplatin (P) combination in the management of locally advanced non-small cell lung cancer. Annals of Oncology 7, suppl 5: 100, 1996 (abs).
17. Von Hoff DD, Schilsky R, Reichert CM: Toxic effects of cisdichlorodiammine-platinum (II) in man. Cancer Treat Rep 63: 1527-1531, 1979.